News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Patients with Atopic Dermatitis
STAMFORD, Conn. , July 09, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the
View HTML
Toggle Summary Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVAᵀᴹ (CR845/difelikefalin) for Pruritus in Patients with Primary Biliary Cholangitis (PBC)
Completed Phase 1 trial in patients with hepatic impairment established Oral KORSUVA tablet strength STAMFORD, Conn., June 26, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to
View HTML
Toggle Summary Cara Therapeutics to Present at the Jefferies 2019 Healthcare Conference
STAMFORD, Conn. , May 31, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a
View HTML
Toggle Summary Cara Therapeutics Announces Positive Results From KALM-1 Pivotal Phase 3 Trial of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
- Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.000019) – - Statistically significant improvement in key secondary endpoint of proportion of patients with four
View HTML
Toggle Summary Cara Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
STAMFORD, Conn. , May 08, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus by selectively targeting peripheral kappa opioid receptors, today announced a
View HTML
Toggle Summary Cara Therapeutics Reports First Quarter 2019 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn. , May 07, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus as well as pain by selectively targeting
View HTML
Toggle Summary Cara Therapeutics to Announce First Quarter 2019 Financial Results on May 7, 2019
STAMFORD, Conn. , April 30, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today
View HTML
Toggle Summary Cara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
STAMFORD, Conn. , April 02, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors,
View HTML
Toggle Summary Cara Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
Conference call today at 4:30 p.m. ET STAMFORD, Conn. , March 12, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on pruritus as well as pain by selectively targeting
View HTML
Toggle Summary Cara Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
STAMFORD, Conn. , March 05, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities with a primary focus on the treatment of pruritus by selectively targeting peripheral kappa opioid receptors, today
View HTML